The global epiglottitis treatment demand is presently valued at around USD 10 Billion and is forecasted to develop at a CAGR of 4.8% to reach USD 16 Billion by 2032. As of 2021, the market was valued at USD 9.7 Billion, and is slated to register a Y-o-Y growth rate of 3.1% by 2022.
There is a huge spike in the prevalence of the disease is likely to significantly contribute to the epiglottitis treatment market. The spike in the diagnosis of the abovementioned condition as well as developing medical infrastructure is anticipated to surge the demand for epiglottitis treatment in this region during the forecast period.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | USD 9.7 Billion |
| Expected Market Value (2022) | USD 10 Billion |
| Anticipated Forecast Value (2032) | USD 16 Billion |
| Projected Growth Rate (2022 to 2032) | 4.8% CAGR |
Epiglottitis is a bacterial viral infection that causes inflammation and swelling of the epiglottis. The epiglottis is a cartilage structure located at the back of the throat, beneath the tongue, and its function is to close over the trachea when foods are swallowed. Epiglottitis causes breathing problems, tachycardia, swelling of supraglottic tissue, inspiratory stridor, pharyngitis, cervical lymph nodes, and inability to deal with secretion.
Drooling, dysphagia, dysphonia, and distressed inspiration efforts are all symptoms of epiglottitis. Adult epiglottitis differential diagnosis includes Infectious process and non-infectious disease, infectious process symptoms include diphtheria, pertussis, croup, tracheobronchitis, peripharyngeal, and others, and non-infectious disease symptoms include allergic reaction, angioneurotic, oedema, reflex laryngospasm, systemic lupus, and others.
Epiglottitis can affect people of any age; however, it is usually diagnosed in males rather than females and occurs in children aged 2 to 8 years. Epiglottitis is primarily caused by Haemophilus influenzae type B (HIB), but other bacteria and viruses such as Streptococcus pneumonia, Streptococcus A, B, and C, and Staphylococcus aureus can also cause epiglottitis inflammation.
A blood test to identify bacteria, an x-ray, and a CT scan to determine the level of swelling are used to diagnose epiglottitis. Epiglottitis is treated with an oxygen mask, which delivers oxygen to the lungs, and a tracheostomy, which may be required to bypass the swelling in the throat.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
During the forecast period, the increasing prevalence and incidence rate of epiglottitis are expected to contribute to the growth of the Epiglottitis Treatment market. HIB vaccination and third generation cephalosporin, which is administered via the parental route (intramuscular/intravenous) and is effective against Haemophilus influenzae type B, which causes Epiglottitis disease, is expected to drive the Epiglottitis Treatment market.
Because epiglottitis is an inflammatory disease caused by a variety of organisms, antibiotics and the combination of an intravenous ant staphylococcal agent are expected to grow significantly during the Epiglottitis Treatment market forecast period. Furthermore, the soaring unhealthy lifestyle combined with lack of cleanliness is anticipated to boost the market’s growth.
Even though epiglottitis treatment is flourishing, there are still some factors impeding the growth of the worldwide epiglottitis treatment market. Epiglottitis Treatment drugs can occasionally cause depression and other side effects, limiting the Epiglottitis Treatment market's growth. The primary restraint of the Epiglottitis Treatment market is a lack of access to healthcare facilities, affordability constraints, and a lack of market penetration of approved drugs.
The Epiglottitis Treatment market in Asia Pacific is projected to thrive at a substantial CAGR of 4.5% over the assessment period from 2022 to 2032. The inclusion of one of the largest economies, such as India and China, is projected to boost the market of the APAC epiglottitis treatment market. As a result of the availability of funds for research and development, this region is expected to observe significant growth in the epiglottitis treatment market.
On the other hand, APAC is further experiencing prominent growth prospects in the epiglottitis treatment market due to increased bacterial infection prevalence as well as increased investment in healthcare infrastructure.
According to Future Market Insights, North America is predicted to dominate the worldwide Epiglottitis Treatment market with a significant CAGR of 4.9%, due to higher adoption and number of customers using Epiglottitis Treatment, as well as increased awareness about Epiglottitis disease. Around 7 million Americans have weak immune system which is also one of the causes of epiglottitis.
In addition to that, an estimated 1.5 million people over the age of 12 use cocaine each month In the United States which is another cause of epiglottitis. Moreover, due to the recent technological advancements and the presence of a variety of novel drug molecules to improve the treatment procedure in the region, the North America epiglottitis treatment market is anticipated to flourish during the forecast period from 2022 to 2032.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The global epiglottitis treatment market is a moderately fragmented market. Abbott, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Roche Holding AG, and others are some of the market participants identified in the global Epiglottitis Treatment market.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5% from 2022 to 2032 |
| Market Value in 2022 | USD 10 Billion |
| Market Value in 2032 | USD 16 Billion |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Type, Route of Administration, End User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, Russia, BENELUX, China, Japan, South Korea, GCC, South Africa, Turkey |
| Key Companies Profiled | Abbot; Merck & Co., Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Pfizer Inc.; Sanofi; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline Plc.; Johnson & Johnson; Roche Holding AG |
| Customization | Available Upon Request |
FMI projects the global epiglottitis treatment market to expand at a 5% value CAGR by 2032
Asia Pacific is expected to be the most opportunistic Epiglottitis Treatment market, expanding at a 4.5% CAGR
Abbott, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Johnson & Johnson and Roche Holding AG, are some prominent Epiglottitis Treatment manufacturers
| Estimated Size, 2024 | USD 12.1 billion |
|---|---|
| Projected Size, 2034 | USD 18.7 billion |
| Value-based CAGR (2024 to 2034) | 4.4% |
| Market Estimated Size in 2023 | USD 1,948.90 million |
|---|---|
| Projected Market Value in 2033 | USD 3,230.90 million |
| Value-based CAGR from 2023 to 2033 | 5.20% |
| Market Value 2023 | USD 18.07 billion |
|---|---|
| Market Value 2033 | USD 55.07 billion |
| CAGR (2023 to 2033) | 11.8% |
| Market Size (2022E) | USD 146.6 Million |
|---|---|
| Projected Size (2032F) | USD 219.10 Million |
| Value CAGR (2023 to 2033) | 4.1% |
Explore Therapy Area Insights
View Reports
Epiglottitis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
